Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis



Status:Completed
Conditions:Chronic Pain, Anemia
Therapuetic Areas:Hematology, Musculoskeletal
Healthy:No
Age Range:12 - 60
Updated:9/26/2018
Start Date:May 2010
End Date:December 2013

Use our guide to learn which trials are right for you!

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis

GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of
this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away
in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study
will also collect information on the safety of GMI-1070, how much of the drug is in the blood
and urine, and if there are any other effects when used in patients who are in the hospital
for a sickle cell pain crisis.

Patients being admitted to the hospital for pain crisis may be eligible for this study. In
addition, patients should be 12-60 years old and have sickle cell types SS or
S-beta-thalassemia. People who take part in the study will be evaluated and then randomly
assigned to receive either GMI-1070 or a placebo by IV, in addition to all other usual
treatments for their pain crisis.

During the hospital stay for pain crisis, GMI-1070 or placebo will be given twice a day, and
patients will be asked about their pain severity (pain score) at the beginning of the study
and every few hours during their hospital stay. Their general health, vital signs, lab tests,
and pain medications will also be checked on a regular basis through the hospital stay. When
a patient is feeling well enough to go home, the study drug (GMI-1070 or placebo) will be
stopped, and the patient may go home. Participants will be asked to come back to clinic for a
check-up a few days after leaving the hospital, and one month after leaving the hospital.

Inclusion Criteria:

1. 12 to 60 years of age

2. Confirmed diagnosis of sickle cell disease (HbSS or HbS-β0thalassemia)

3. Diagnosis of VOC at the time of enrollment

4. Hospitalized or in process of admission at the time of enrollment

5. Able to receive the first dose of study drug within 24 hours of initial medical
evaluation in the Emergency Department/clinic for VOC;

o Subjects treated as an outpatient within the past 48 hours for the same VOC episode
may be enrolled if dosing is also expected within 24 hours of their second (admitting)
presentation.

6. Documented and observed written informed consent (and assent, where applicable)

Exclusion Criteria:

1. Infection, diagnosed or strongly suspected, as evidenced by one or more of the
following:

- Fever >39°C (102.2°F)

- In the presence of fever ≥38.5°C (101.3°F), 1 of the following:

- Positive findings (suspicious for infection) on diagnostic tests, such as
cerebral spinal fluid [CSF] evaluation, radiographs, or bacterial culture of
normally sterile sites

- Exam findings leading to diagnosed or strongly suspected bone or joint
infection

- Determination by physician that bacterial or serious systemic viral
infection is likely (eg, influenza, mononucleosis)

- Subjects may be included with uncomplicated urinary tract infections
(provided they do not have fever ≥38.5° C [101.3° F] or costo-vertebral
angle [CVA] tenderness), and/or suspected minor viral syndromes (upper
respiratory infection symptoms but no symptoms suggestive of bacterial
infection other than uncomplicated otitis media or uncomplicated
streptococcal pharyngitis)

2. Acute chest syndrome, diagnosed or strongly suspected, as evidenced by a new
infiltrate on chest radiograph, and 1 or more of the following:

- Fever >39° C (102.2° F)

- Hypoxia (confirmed by arterial blood gases [ABG] with paO2 <70 mmHg)

- Chest pain

- Suspicious findings on exam (tachypnea, intercostal retractions, wheezing, and/or
rales)

3. Sickle cell disease (SCD) pain atypical of VOC, including hepatic or splenic
sequestration, cholecystitis, or pneumonia.

4. Acute stroke, acute priapism, severe avascular necrosis of the hip/shoulder when the
presenting pain is only in the affected hip/shoulder

5. Serum creatinine:

- >1.2 mg/dL for subjects 16 to 60 years of age

- >1.0 mg/dL for subjects 12 to 15 years of age

6. Alanine transaminase (ALT/SGPT) >2x upper limit of normal (ULN) (based on clinic
laboratory normal range)

7. Hemoglobin <5 g/dL

8. Platelets <100,000/mm3

9. Recent (within the past 30 days) major surgery, hospitalization for other than VOC,
documented serious bacterial infection requiring antibiotic treatment, or significant
bleeding

10. Hospitalization for uncomplicated VOC, or treated with parenteral pain medications in
other medical settings such as the emergency department or day hospital for
uncomplicated VOC, within past 14 days.

o Subjects may be included if treated as an outpatient within the past 48 hours for
the same VOC episode.

11. Recent (within the past 90 days) cerebrovascular accident, transient ischemic attack,
or seizure

12. pRBC transfusions in the past 14 days

13. Systemic steroid therapy within 48 hours prior to enrollment or expectation that
therapy may be used during the study (inhaled or topical steroids are allowed)

14. For those on chronic or long-acting opioids, a change in dose in the past 14 days OR
pain requiring medical attention in the past 14 days (change in opioid medication for
acute pain in the past 48 hours and directly related to this VOC admission is allowed)

15. Greater than 5 episodes of hospitalization for VOC in the past 6 months (180 days)

16. Medical or psychiatric condition that, in the opinion of the investigator, may pose a
risk to the subject for participation or interfere with the conduct or results of the
study

17. Currently receiving, or has received within the previous 4 weeks, any other
investigational agent

18. Previous administration of GMI-1070

19. Expectation that the subject will not be able to be followed for the duration of the
study

20. Pregnant or lactating female; or female of childbearing potential or male unable or
unwilling to comply with birth control methods or abstinence during the course of the
study

21. Active use of illicit drugs and/or alcohol dependence, as determined by the
investigator
We found this trial at
22
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
1601 Northwest 12th Avenue
Miami, Florida 33136
(305) 243-6545
University of Miami Miller School of Medicine The University of Miami Leonard M. Miller School...
?
mi
from
Miami, FL
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1459 Laney-Walker Blvd
Augusta, Georgia 30901
(706) 721-3052
Georgia Health Sciences University Georgia Regents University, home of the Medical College of Georgia, is...
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21287
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Berkeley, California
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02118
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York 10467
?
mi
from
Bronx, NY
Click here to add this to my saved trials
506 6th St
Brooklyn, New York 11215
(718) 780-3000
New York Methodist Hospital A voluntary, acute-care teaching hospital, New York Methodist Hospital's mission is...
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
(312) 996-4350
University of Illinois at Chicago A major research university in the heart of one of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45229
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
263 Farmington Ave
Farmington, Connecticut 06030
(860) 679-2000
University of Connecticut Health Center UConn Health is a vibrant, integrated academic medical center that...
?
mi
from
Farmington, CT
Click here to add this to my saved trials
3414 Fifth Avenue
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
2315 Stockton Blvd.
Sacramento, California 95817
(916) 734-2011
University of California, Davis Medical Center UC Davis Medical Center serves a 65,000-square-mile area that...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
?
mi
from
Toronto,
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials